drugset / Trial / NCT03202992

Study of Topical ABI-1968 in Subjects With Precancerous Anal Lesions Resulting From Human Papillomavirus (HPV) Infection

NCT03202992 ↗

Phase 1 Completed 57 enrolled Antiva Biosciences
Non-randomizedSequentialOpen-labelTreatment

Summary

This study evaluates the use of ABI-1968, a topical cream, in the treatment of anal precancerous lesions in adults with and without human immunodeficiency virus (HIV) infection.

Timeline

Start
2017-08-11
Primary completion
2019-02-04
Completion
2019-02-04

Drugs

EvaluationDrugModalityDoseRoute
Subject ABI-1968 Unknown — Topical